Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986956 · ClinicalTrials.gov registry record · NA
Whole Coffee Cherry Study
A NA study, sponsored by Auburn University.
- Completed
- Registry status
- NA
- Development phase
- 323
- Enrollment target
NCT04986956: Completed NA study, sponsored by Auburn University.
NCT04986956 is a NA study that has completed, run by Auburn University. The registered enrollment target is 323 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04986956, a NA study, has completed, sponsored by Auburn University.
- COMPLETED
- Registry status
- NA
- Development phase
- 323 participants
- Enrollment target
Study Summary
There has been increasing interest in natural dietary supplements that may support healthy cognition. Recent studies have demonstrated promising effects of bioactive phytochemicals (e.g., polyphenols) on cardiovascular and endocrine health outcomes. As such, an increasingly intriguing line of inquiry is whether materials high in these compounds may also have effects on psychological measures. Preliminary evidence suggests that polyphenols may improve cognition, for example, particularly in aging populations. Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (\<2%; \<4mg) levels of caffeine. WCCE has been previously associated with increased serum concentrations of both circulating and exosomal brain derived neurotrophic factor (BDNF), in addition to increased alertness and decreased fatigue. However, few well-powered and well-designed studies have been conducted despite the mounting preliminary evidence. Here, the investigators propose a study to examine the long-term effects of a 200mg dose of WCCE on measures of cognition.
Primary Outcome
Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Whole coffee cherry extract
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2024-01-29 |
| Phase | NA |
What the finished NCT04986956 record still lists
NCT04986956 is an interventional study that assigns participants to a tested intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04986956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04986956 about?
NCT04986956 is a clinical study titled "Whole Coffee Cherry Study". There has been increasing interest in natural dietary supplements that may support healthy cognition. Recent studies have demonstrated promising effects of bioactive phytochemicals (e.g., polyphenols) on cardiovascular and endocrine health outcomes. As such, an increasingly intriguing line of inquir...
What is the current status of trial NCT04986956?
This trial is currently completed. It is a NA study. The enrollment target is 323 participants. The study started on 2022-02-01. Estimated completion is 2024-01-29.
What interventions are being tested in trial NCT04986956?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Whole coffee cherry extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04986956?
This trial is sponsored by Auburn University, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04986956's enrollment target sits among peer trials
323 315th of 2000 higher than 1,686 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI